Professur für Molekulare Mechanismen der Organfibrose

EFFECTS OF THE AUTOTAXIN INHIBITOR ZIRITAXESTAT ON SKIN AND LUNG FIBROSIS IN A MURINE GRAFT-VERSUS-HOST DISEASE MODEL OF SYSTEMIC SCLEROSIS (2021) Zhang Y, Summa L, Heckmann B, Distler J Conference contribution INACTIVATION OF ALDEHYDE DEHYDROGENASE 3A2 INHIBITS FIBROBLAST ACTIVATION AND TISSUE FIBROSIS (2021) Xu X, Li YN, Chen CW, Trinh-Minh T, Schett G, Distler J Conference contribution 68GA-FAPI-04 PET/CT STUDY EXTENSION FOR THE ASSESSMENT OF FIBROBLAST ACTIVATION AND RISK EVALUATION IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE (2021) Bergmann C, Distler J, Treutlein C, Tascilar K, Müller A, Atzinger A, Matei AE, et al. Conference contribution EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT (2021) Kuster S, Jordan S, Elhai MD, Held U, Steigmiller K, Bruni C, Iannone F, et al. Conference contribution PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING (2021) Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, Chatelus E, et al. Conference contribution DECLINE IN FORCED VITAL CAPACITY (FVC) IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL VERSUS HYPOTHETICAL REFERENCE SUBJECTS WITHOUT LUNG DISEASE (2021) Maher T, Bourdin A, Volkmann E, Vettori S, Distler J, Alves M, Stock C, Distler O Conference contribution CIRCULATING MONOCYTES HAVE DISTINCT PHYSICAL PROPERTIES THAT CORRELATE WITH DISEASE ACTIVITY AND SEVERITY AND PREDICT PROGRESSION IN SYSTEMIC SCLEROSIS (2021) Matei AE, Kubankova M, Györfi A, Boxberger E, Soteriou D, Papava M, Muth J, et al. Journal article S100A4 PLASMA LEVELS CORRELATE WITH DISEASE ACTIVITY, SKIN FIBROSIS AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS (2021) Storkanova H, Cerezo LA, Oreska S, Spiritovic M, Hermankova B, Komarc M, Pavelka K, et al. Conference contribution Inhibition of Hsp90 counteracts the established experimental dermal fibrosis induced by bleomycin (2021) Štorkánová H, Štorkánová L, Navrátilová A, Bečvář V, Hulejová H, Oreská S, Heřmánková B, et al. Journal article Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease (2021) Zhang Y, Shen L, Dreißigacker K, Zhu H, Trinh MT, Meng X, TRAN MANH C, et al. Journal article